US FDA orders new warnings for GLP-1 drugs over rare vision loss risk

FDA mandates label updates for drugs

The agency required manufacturers to add information about non-arteritic anterior ischemic optic neuropathy to the warnings section of medicine labels. This condition reduces blood flow to the front of the optic nerve and can cause sudden, painless deterioration of vision in one eye. Individuals may experience reduced central sharpness, distorted colors, tunnel vision, blind spots, and blurred vision for the first time upon waking. Individuals should reach out to a medical provider right away upon noticing abrupt or unclear alterations in their sight.

Analysis reveals higher incidence rates

A review of 126 randomized controlled trials involving 134,253 patients found 10 likely NAION instances in individuals taking GLP-1 medications. In contrast, five cases were recorded in the placebo group while no such instances occurred among participants taking alternative glucose-lowering medications. The calculated incidence rates were 6.4 cases per 100,000 person-years for GLP-1 users versus 3.8 cases per 100,000 person-years in comparison groups. An independent FDA investigation revealed no statistically significant rise when contrasting these drugs with SGLT-2 inhibitors, yet it highlighted an elevated risk relative to DPP-4 inhibitors.

Doctors weigh benefits against risks

The agency advised patients not to stop taking GLP-1 medicines without medical guidance while people who previously experienced NAION should discuss continuing treatment with their doctors. The condition's current risk factors encompass smoking, diabetes, hypertension, sleep apnea, anemia, and kidney disease. Individuals suffering from this issue in a single eye face an increased chance of acquiring it in their second eye.